Amdocs Ltd (DOX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Amdocs Ltd stock $121, price $42.09, upside +188.2%, quality 76 out of 100. Rating: strongly undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
TechnologyUS · Home United Kingdom · ISIN GB0022569080
ALBroad dataNov 6, 2026
Amdocs Ltd
DOX · US
Undervalued,but in a downtrend
The stock costs 65% less than our calculation considers fair.
Fair value $121.31 · Strongly undervalued
Quality 76/100
Solidly profitable · 10.6% net margin (TTM)
Low debt
Generates free cash flow
5.3% dividend yield · Well covered
Ranks above peers(13/15)
Upbeat coverage
Broad data
Even on cautious assumptions the value is 92% above the price ($80.62).
Moderate moat63/100
Insiders sold $29,005 (6M)
Weak Growth(revenue 5y +1.7 %/yr in USD)
Risks from the AI analysis
🚩Price drop: Guidance for material revenue drop due to T-Mobile dispute🚩Legal dispute that could end T-Mobile contracts🚩Generative AI could reduce demand for consulting services🚩Dependence on a few large telecom customers with dispute risk
Watch Amdocs Ltd for free: we tell you when fair value or trend changes.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $42.09 – $90.60 · fair‑value band $80.62 – $157.70 · the $42.09 price screens below the $121.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Amdocs in your weekly email
Every Wednesday you see whether Amdocs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Amdocs Limited, through its subsidiaries, provides software and services to communications, entertainment, media, and other service providers worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud offering.
Show moreShow less
The company also provides CES25, a telco-native, GenAI-led customer experience suite, spanning business, and operations and network domains that is embedded with AI and related tools.
In addition, it offers GenAI agents, and which include Customer Engagement Platform, a telecom-specific customer relationship management (CRM) solution; Amdocs Monetization Suite which enables customers to monetize their broad set of services and offerings; Amdocs Intelligent Networking Suite, a set of solutions that provide end-to-end service orchestration; Amdocs Charging; Amdocs eSIM Cloud that enables service providers to offer digital SIM (eSIM); Amdocs MarketONE, a based Software-as-a-Service (SaaS)-based platform that includes pre-integrated digital services, ranging from media, gaming, eLearning, sports and retail to security, and business services; and Amdocs connectX, a cloud-native telco-in-a-box software-as-a-service platform for digital telecom brands, as well as Amdocs CatalogONE that spans the entire CES25 suite and combines embedded business intelligence with telecom-specific GenAI agents.
Further, the company provides consulting, experience design, data, cloud, network services, delivery, quality engineering, operations, systems integration, and content services to various platforms and technologies; maintenance, enhancement design and development, and operational support services; network deployment and optimization services; and managed services, including AI and related tools, predictive analytics, and robotic process automation, as well as quality engineering, mobile network, cloud, and professional services.
Amdocs Limited was founded in 1982 and is headquartered in Saint Louis, Missouri.
Stock analysis
Amdocs Ltd (DOX) currently trades at $42.09, while our model-based Fair Value estimate is $121.31, implying the stock looks roughly 65% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $124.57 per share, and 20 of the 25 models we run sit above the $42.09 price.
Bear case: the Dividend Discount group reads lowest at $34.56, and 5 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: $80.62 (bear) to $157.70 (bull), the price of $42.09 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Technology sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Amdocs Ltd reported revenue of $4.5B in FY2025 versus $4.3B in FY2021, a compound +1.4%/yr. Reported net income was $565M in FY2025, compounding −4.8%/yr from FY2021.
Key figures
Market cap $4.4B Mid · P/E ratio 9.0 · P/S ratio 0.95 · EPS (TTM) $4.68 · Dividend yield 5.3% · Net margin 10.6% · Return on equity 14.7% · Return on assets (EBIT) 10.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 49% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −11% fair-value upside, at 188%, DOX screens cheaper than that median.
Fair Value models
Bear$80.62Fair Value $121.31Bull$157.70
Price $42.09 · Upside +188.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($2.45 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $29,005 and none bought.
SaleMatthew E. SmithOfficer464 shares at $62.51$29,005May 29, 2026
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Start year 2020 (pandemic). Over 10 years: +2.2% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+12.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.0%
Dividend (yield on the price)5.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.2% vs 6.4%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 18%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −12.7% a year for the price and −1.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Long-term contracts underpin moderate moat potential and stable returns, while thin public signals limit any durability assessment.
Main risk: Generative AI might automate implementation, customization and maintenance work that accounts for much of Amdocs revenue, squeezing margins on its core telecom software and services offerings.
Bull case: Amdocs could leverage its aOS agentic platform and deep telco integrations to become the preferred orchestrator of AI-driven operations for carriers, expanding into new verticals like insurance and sustaining or growing managed-services revenue.
Bear case: If AI automates large parts of its traditional services and key customers reduce spend or terminate contracts amid disputes, Amdocs could face prolonged revenue declines and margin pressure in its core telecom business.
Amdocs reports solid recent results and expects mid-single-digit growth in most of its telecom business yet guides for a material revenue drop next year because of a legal dispute that could end contracts with T-Mobile. The company is also acquiring an insurance software firm to broaden beyond its traditional customers. Our models see it as undervalued. Will the rest of the platform and new markets deliver enough to offset concentration in a handful of carriers?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Infrastructure · 346 stocks
Beats the industry median on 13/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside+188.2% · Top 25%
Profitability
Return on equity (12 months)14.7% · Above median
Return on assets9.0% · Top 25%
Net margin (12 months)10.6% · Above median
Operating margin (12 months)18.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)3.8% · Below median
Dividend yield (12 months)5.3% · Top 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Software - Infrastructure median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Amdocs Ltd Fair Value". https://www.fairvalue-calculator.com/stock/DOX
Frequently asked questions
Is Amdocs Ltd (DOX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $121.31 versus a price of $42.09, about +188% upside (undervalued).
What is the fair value of DOX?
Our model-based fair value for Amdocs Ltd is $121.31 (as of Nov 6, 2026), built from audited fundamentals. The current price: $42.09.
What is the quality score of DOX?
Amdocs Ltd has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amdocs Ltd (DOX)?
Our model-based price target is the fair value of $121.31 (as of Nov 6, 2026) from 25 valuation models. Cautious scenario $80.62, optimistic scenario $157.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Amdocs Ltd stock forecast for 2026?
Our models put fair value at $121.31, about +188% upside versus a price of $42.09 (undervalued). Cautious scenario $80.62, optimistic scenario $157.70. The calculation is refreshed regularly with new filings.
What is the revenue of Amdocs Ltd (DOX)?
Amdocs Ltd reported trailing-twelve-month revenue of about $4.7B (latest available figure, as of Nov 6, 2026).
Does Amdocs Ltd pay a dividend?
Amdocs Ltd currently shows a dividend yield of 5.31% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Amdocs Ltd (DOX) and when is the ex-dividend date?
Amdocs Ltd pays a dividend of $2.23 per share a year, a dividend yield of 5.3%. The last ex-dividend date was Sep 30, 2026. A dividend has been paid every year since at least 2012. The payout ratio is 47.7% of earnings. Free cash flow covers the dividend 2.77 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Amdocs Ltd (DOX)?
For today's price to be fair in a discounted-cash-flow model, Amdocs Ltd would have to grow free cash flow by -10.7 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.7 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of DOX use?
Our models discount Amdocs Ltd at 8.5 %: a base by market capitalisation (mid), damped by beta 0.42, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Amdocs Ltd that is -10.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Amdocs Ltd (DOX) delivered so far?
Over the past 5 years revenue at Amdocs Ltd grew +1.7 % a year. The price currently implies free-cash-flow growth of -10.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Amdocs Ltd (DOX) growing?
The median revenue growth in the sector is +11.5 % a year. That is the yardstick for the growth priced into Amdocs Ltd (-10.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Amdocs Ltd (DOX)?
The free-cash-flow yield on the price is 14.50 %: that much free cash flow Amdocs Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Amdocs Ltd (DOX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amdocs Ltd it is $121.31 per share (as of Nov 6, 2026), against a price of $42.09. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Amdocs Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, DOX trades below its calculated fair value: price $42.09, fair value $121.31, a gap of about +188% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOX?
No. The price is what the market pays today ($42.09); the fair value is what the company's own numbers justify ($121.31). For Amdocs Ltd the two are $79.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amdocs Ltd worth?
The market values Amdocs Ltd at about $4.4B (market capitalisation, as of Nov 6, 2026). Per share that is $42.09; our models calculate a fair value of $121.31 per share.
What do the bullish and bearish scenarios say about DOX?
Our models span a range for Amdocs Ltd: cautious scenario $80.62, base $121.31, optimistic $157.70 per share (as of Nov 6, 2026, price $42.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DOX?
Amdocs Ltd trades at a price-to-earnings ratio of 9.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $121.31 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2021, FY2023, FY2024 ex one-offs: 18.3. Other multiples: PEG 0.8, P/B 1.3, P/S 0.9, EV/EBITDA 4.6.
What is the PEG ratio of DOX?
The PEG ratio of Amdocs Ltd is 0.84 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Amdocs Ltd (DOX)?
Balance-sheet figures for Amdocs Ltd (as of Nov 6, 2026): return on equity 14.7%, debt of 0.19 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is DOX from its 52-week high?
Amdocs Ltd trades at $42.09, about 49% below its 52-week high of $82.44 and at the low of $42.09 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $121.31 is for.
Which stocks are comparable to Amdocs Ltd?
From the same area (Technology) we also value Microsoft Corporation, Oracle Corporation, Palantir Technologies Inc, Palo Alto Networks, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amdocs Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price $42.09, calculated fair value $121.31 (+188%), Quality Score 76/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DOX calculated?
We run Amdocs Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $121.31 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Amdocs Ltd currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amdocs Ltd (DOX)?
The closing price on Nov 6, 2026 was $42.09. Our model-based fair value is $121.31, about +188% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amdocs Ltd right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($80.62). The market is more pessimistic than our downside scenario. A fairly wide model range ($80.62 to $157.70) leaves room in how you read the outcome.
Where does the earnings growth of Amdocs Ltd (DOX) come from?
Earnings per share at Amdocs Ltd grew +6.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.8 %, EBIT margin +0.7 %, tax rate −0.3 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Amdocs Ltd
How large is the market capitalisation of Amdocs Ltd (DOX)?
The market capitalisation of Amdocs Ltd is $4.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amdocs Ltd (DOX)?
The price-to-sales ratio of Amdocs Ltd is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amdocs Ltd (DOX)?
Earnings per share at Amdocs Ltd are $4.68 (price ÷ EPS = P/E 9.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Amdocs Ltd (DOX)?
The dividend yield of Amdocs Ltd is 5.3% (payout 47.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Amdocs Ltd (DOX)?
The net margin of Amdocs Ltd is 10.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amdocs Ltd (DOX)?
The return on equity (ROE) of Amdocs Ltd is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amdocs Ltd (DOX)?
On an EBIT basis the return on assets of Amdocs Ltd is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amdocs Ltd (DOX)?
The operating margin of Amdocs Ltd is 18.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amdocs Ltd (DOX)?
Revenue at Amdocs Ltd is growing +3.8% versus a year earlier (3y avg −0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amdocs Ltd (DOX)?
Earnings per share at Amdocs Ltd are growing +54.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Amdocs Ltd (DOX) carry?
The net debt of Amdocs Ltd is $501M (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Amdocs Ltd in the live analysis
One click puts Amdocs Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026